Halozyme Therapeutics reported $101.36M in Gross Profit on Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 112.52M 15.68M
Alnylam Pharmaceuticals ALNY:US $ 177.63M 43.24M
Amarin AMRN:US $ 72.39M 41.46M
Amgen AMGN:US $ 4677M 451M
Baxter International BAX:US $ 1350M 58M
Eli Lilly And LLY:US $ 5737.9M 211.8M
Esperion Therapeutics ESPR:US $ 11.71M 1.38M
Halozyme Therapeutics HALO:US $ 101.36M 20.94M
Intercept Pharmaceuticals ICPT:US $ 87.82M 3.57M
Intra Cellular Therapies ITCI:US $ 31.84M 8.71M
Intrexon XON:US $ 6.11M 12.44M
JAZZ PHA JAZZ:US $ 698.44M 62.14M
Mannkind MNKD:US $ 0.99M 0.09M
Nektar Therapeutics NKTR:US $ 18.85M 0.76M
Peregrine Pharmaceuticals PPHM:US $ 9.19M 2.2M
Pfizer PFE:US $ 15651M 1516M
United Therapeutics UTHR:US $ 436M 55.4M